Frederick T Mattrey

Title: Innovations of Frederick T. Mattrey: Advancing Metabolic Syndrome Treatments

Introduction: Frederick T. Mattrey, an accomplished inventor based in Bridgewater, NJ, has made significant contributions to the field of pharmacology. With a focus on treating conditions associated with Metabolic Syndrome, his innovative work has the potential to impact the lives of many patients struggling with related health issues.

Latest Patents: Frederick T. Mattrey holds a patent for "Crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1." This invention features novel crystalline salts of the compound 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole. These salts serve as potent inhibitors of 11β-hydroxysteroid dehydrogenase Type 1, providing a promising avenue for the treatment of various conditions linked to Metabolic Syndrome and cognitive impairments. The patent also includes pharmaceutical compositions containing these new salts, along with processes for their preparation and applications in treating Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.

Career Highlights: Frederick has had a notable career at Merck Sharp & Dohme Corporation, where he has dedicated his efforts to innovative research that addresses critical health challenges. His inventiveness and dedication to pharmaceutical development underscore his role in advancing medical science.

Collaborations: Throughout his career, Frederick has collaborated with talented coworkers, including Joseph E. Lynch and Yuri Y. Bereznitski. These partnerships have fostered an environment of collective innovation and research excellence, contributing to the success of their various projects.

Conclusion: Frederick T. Mattrey exemplifies the spirit of innovation within the pharmaceutical sector. With his patent on inhibitors targeting 11-β-hydroxysteroid dehydrogenase type 1, he stands at the forefront of developments aimed at improving the health of individuals affected by Metabolic Syndrome. His ongoing contributions at Merck Sharp & Dohme Corporation highlight the critical role that inventors play in shaping the future of medicine.